Helex Email Format
Biotechnology ResearchNew York, United States11-50 Employees
Helex is a biotechnology research company focused on delivering genetic medicines to the kidney through non-viral methods. It combines a proprietary kidney-tropic lipid nanoparticle delivery system with a 3D genome-based drug design platform to create renal-focused therapeutics. The lead asset targets Autosomal Dominant Polycystic Kidney Disease and is described as mutation-agnostic, potentially providing a single-dose therapy for a disease affecting more than four million people worldwide. The company is based in New York City, New York, and operates with a relatively small team. Within the biotechnology sector, Helex positions itself around non-viral, kidney-targeted delivery and genome-based design to develop first-in-class therapies for kidney indications. Its focus is on durable, scalable renal treatments aimed at addressing a broad patient population.